Bayer forms joint venture in Russia; Aerie Pharma reviews upbeat data for glaucoma drug;

 @FierceBiotech: Roche, pharma slice and dice DNA data to exploit cancer weaknesses. Story | Follow @FierceBiotech

 @JohnCFierce: Bloomberg's sized up the PCSK9 rivalry between Amgen and Sanofi/Regeneron. Article | Follow @JohnCFierce

 @RyanMFierce: Any idea what uniQure's gene therapy should cost? Here's our report on approval in EU. More | Follow @RyanMFierce

> Bayer Healthcare has joined forces with Russian drugmaker Medsintez to produce diagnostic imaging agents and pharmaceuticals for patients in Russia. Release

> Aerie Pharmaceuticals generated upbeat results in a Phase IIa trial of its therapy called AR-13324 for patients with glaucoma. Release

> RayBiotech has tapped Abeome for 300 monoclonal antibodies focused on ovarian cancer. Item

> Digna Biotech, a Spain-based biotech focused on liver diseases, has opened its first U.S. office in Pennsylvania. Article

> Isis ($ISIS) has received a $1.25 million payment from Pfizer ($PFE) because of Pfizer's decision to advance development of EXC 001 or PF-06473871. Release

> Montreal-based Alethia Biotherapeutics, a developer of monoclonal antibodies against bone disases, raised $4.7 million from AgeChem Venture Fund, BDC Venture Capital, GO Capital and Cellscript. Release

Pharma News

@FiercePharma: ICYMI yesterday: Top 15 drug patent losses for 2013. The patent cliff isn't over. Report | Follow @FiercePharma

> U.K. finally approves Roche's Zelboraf and BMS' Yervoy. Article

> J&J settles a boatload of Levaquin cases. News

> After Wellbutrin fiasco, FDA takes a look at generic equivalence. Story

Medical Device News

 @FierceMedDev: St. Jude announced it is cutting 500 more jobs in through its restructuring plan. 8-K | Follow @FierceMedDev

 @MarkHFierce: Taiwan wants to get on the medical device bandwagon and has plans to jumpstart its local industry. News | Follow @MarkHFierce

 @DamianFierce: Ex-Stryker CEO Stephen MacMillan has landed on his feet after the public breakup, taking the reins at sBioMed. More | Follow @DamianFierce

> Report: European Commission must speed up creation of tougher medical implant regs. Story

> Ex-Stryker CEO to head disinfectant firm. Item

> Investors punish Abiomed over Impella investigation news. Report

And Finally… More stuff to worry parents: Researchers find that food allergies in children can make them bull's-eyes for bullies. Report

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.